RxDoctor Payments Data

Herbert Mayer, MD

Gastroenterology · New Orleans, LANPI 1447225537

Payments from drug & device makers

$5,113in general payments, 2019–2025

Across 336 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$506
  • Pfizer$403
  • Takeda Pharmaceuticals U.S.A., Inc.$305
  • Bristol Myers Squibb$295
  • Gilead$174
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$5,06299%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,113 in reported general payments places this provider in the 55th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$82,983
Medicare patients
278
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab15$101,763
Xeljanz XrTofacitinib Citrate11$68,544
LinzessLinaclotide79$60,236
XifaxanRifaximin12$42,195
ClenpiqSod Picosulf/Mag Ox/Citric Ac73$12,258
TrulancePlecanatide12$9,121
Famotidine325$6,024
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag37$4,653
Dicyclomine Hcl180$4,354
Pantoprazole Sodium433$3,639
Mesalamine13$3,416
Dexlansoprazole DrDexlansoprazole20$2,950
CholestyramineCholestyramine (With Sugar)36$2,669
SutabSod Sulf/Pot Chloride/Mag Sulf15$2,489
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C12$1,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,311$60,23679 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$506$52,99936 claims
Ferring Pharmaceuticals Inc.Clenpiq$22$12,25873 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →